56672-56-1

Usage

Also known as

3,4-Methylenedioxyphenyl hydroxypropylamine (MDBD)

Classification

Psychoactive substance belonging to the phenethylamine and amphetamine class of drugs

Derivative of

MDMA (ecstasy)

Chemical structure

Closely related to MDMA with similar properties like enhancing mood, increasing energy, and heightening sensory experiences

Potency

Less potent than MDMA with a shorter duration of action

Usage

Primarily used recreationally for euphoric and empathogenic effects

Safety profile

Not well-understood in terms of potential for addiction and dependence

Upstream product

• 120-57-0 piperonal 
• 56-40-6 glycine 

Downstream Products

• 1458647-14-7 2-phthalimido-3-hydroxy-3-(3,4-methylenedioxyphenyl)propionic acid 
• 123474-73-7 4-keto-2-azapodophyllotoxin 

Relevant academic research and scientific papers

COMPOSITIONS AND METHODS FOR THE TREATMENT OF ORTHOSTASIS AND NEUROLOGICAL DISEASES

The invention relates to the compounds of formula I and formula II or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of

METHOD OF DROXIDOPA SYNTHESIS

The present application relates to a novel method of preparing L-threo-dihydroxyphenylserine (droxidopa). Specifically, the application is directed to a method of preparing droxidopa via a deprotection step that is an alternative to deprotection steps tha

SYNTHESIS OF 2-AZA-4-KETOPODOPHYLLOTOXIN

A synthesis of 2-aza-4-ketopodophyllotoxin (7), a key intermediate of 2-azapodophyllotoxin (1), is reported.

Process for producing threo-3-(3,4-dihydroxyphenyl)serine

A process for producing an optically active threo-3-(3,4-dihydroxyphenyl)serine represented by the formula STR1 which is useful as a remedy for peripheral orthostatic hypotension or as an antidepressant, which process comprises treating threo-3-(3,4-methy